Promising Phase 2 Results for Vidofludimus Calcium in Progressive Multiple Sclerosis Highlight Potential for Neuroprotection and Disease Modification

Immunic (IMUX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.

Matthew Caufield has given his Buy rating due to a combination of factors related to the promising results of the Phase 2 CALLIPER trial for Immunic’s vidofludimus calcium in progressive multiple sclerosis (PMS). The trial results indicate that the oral candidate vidofludimus calcium supports neuroprotection and impacts disease progression independently of relapse activity, which is a significant distinction from existing treatments that primarily address relapsing MS. This differentiation highlights the potential for vidofludimus calcium to slow neurodegeneration, benefiting both non-active and active disease patients.
Additionally, vidofludimus calcium’s dual mode-of-action, involving neuroprotection through Nurr1 activation and relapse prevention via DHODH inhibition, positions it as a promising candidate for future Phase 3 development. The trial demonstrated a reduction in confirmed disability worsening events, particularly in primary progressive MS patients, and showed benefits in patients without gadolinium-enhancing lesions. These findings, along with the ongoing pivotal Phase 3 trials in relapsing MS patients, suggest that vidofludimus calcium could offer a strategic advantage in addressing unmet needs in multiple sclerosis treatment.

Caufield covers the Healthcare sector, focusing on stocks such as Immunic, Unity Biotechnology, and Mineralys Therapeutics, Inc.. According to TipRanks, Caufield has an average return of -17.6% and a 26.45% success rate on recommended stocks.